taking 1/2 off up $10<----- SNOW Snowflake Inc. $156.53 +3.95 (+2.59%)12:41 PM 08/23/23 NYSE | $USD | Realtime
Starting to put together some consecutive up days here-- EPR EPR Properties<-- WATCH $44.240.74 (+1.70%)12:44 PM 08/23/23 NYSE | $USD | Realtime
It was $35 when the selling became rampant and guess what they flopped. SO the FDA gave themn a no go which has recently been amended they6 can start again.. thus the strength. So two ways of looking at this.... $35------------>$15 that's a lot of room to run!! (2) There's a good chance the drug misses trials because of the worry 1st time around.... Lets check OBV and Inst ownership and cash on hand....
It's a tweaky chart MACD has not really turned up. OBV is good but if you watch RS it's stable at 40 something over many months and in the last 5 days has risen. That can be a good sign or a bad sign. I think this will come back in. But yes it is under accum.
They had around $100 mln recently but this financing is of interest-- i mean yea they got the money but they gave away 10%..... Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Millionin Non-Dilutive CapitalMay 4, 2022Upfront payment of $100 million, an additional $160 million available upon FDA approval of vonoprazan for treatment oferosive esophagitis (EE)Provides capital for launch of vonoprazan in H. pylori and EE, if approved, in addition to Phase 3 program in non-erosivereflux disease (NERD)Total royalty payments capped at 2.0x invested capitalFLORHAM PARK, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical companyfocused on developing and commercializing novel treatments for gastrointestinal diseases, today announced a revenue interest financing of up to$260 million in non-dilutive capital. The agreement provides for an upfront $100 million cash payment and an additional $160 million cash paymentupon FDA approval of vonoprazan for treatment of EE.“The signing of this agreement both validates our belief in the blockbuster opportunity of vonoprazan and provides near-term, non-dilutive funding forour continued development activities and upcoming commercial launch. The next twelve months are pivotal for Phathom as we prepare for the U.S.launch of vonoprazan for H. pylori in the third quarter of this year, followed by the potential FDA approval for erosive esophagitis expected in the firstquarter of 2023,” said Terrie Curran, President and Chief Executive Officer of Phathom. “Based on our current operating plan, and with the funds fromtoday’s transaction plus our cash on hand and access to capital under our existing loan agreement, we believe we have sufficient capital to fundoperations through 2024. This includes supporting the launch of vonoprazan for H. pylori and in EE, if approved, in addition to financing our dailydosing Phase 3 trial in NERD. We are thrilled to partner with firms who share our belief in Phathom’s significant opportunity and mission to improve thetreatment landscape for acid-related disorders.”Sagard Healthcare Partners (“Sagard”), NovaQuest Capital Management (“NovaQuest”) and Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”)(collectively, “the Investors”) have committed to providing $260 million, including the first $100 million payment and commitments for an additional$160 million upon EE approval. The agreement provides Phathom with an option, subject to the Investors’ right of first offer, to increase the paymentsunder the agreement to up to $300 million by adding additional investors for up to an additional $40 million.In exchange for the commitment to provide these cash payments, the Investors will receive a 10% royalty on Phathom’s net sales of productscontaining vonoprazan. The royalty payment will be reduced to 1% on incremental net sales that exceed certain annual thresholds following regulatoryapproval of vonoprazan for symptomatic non-erosive reflux disease, or NERD. The total royalties payable by Phathom to the Investors are capped at 2.0x of the total payments received from the investors. Upon achievement of the cap amount, the royalty agreement will terminate.
You know I have an H pylori problem it's part of my spring sickness -- This is of interest to me-- Phathom Pharmaceuticals (PHAT) In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Phathom Pharmaceuticals, with a price target of $28.00. The company’s shares closed last Monday at $15.04. According to TipRanks.com, Caufield is a 5-star analyst with an average return of 32.2% and a 54.2% success rate. Caufield covers the Healthcare sector, focusing on stocks such as Opthea Limited Sponsored ADR, 4D Molecular Therapeutics, and Aldeyra Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Phathom Pharmaceuticals with a $26.00 average price target, representing a 75.8% upside. In a report issued on August 11, Jones Trading also maintained a Buy rating on the stock with a $27.00 price target.